enzastaurin has been researched along with Non-alcoholic Fatty Liver Disease in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Akazawa, Y; Billadeau, DD; Bronk, SF; Cazanave, SC; Elmi, NA; Gores, GJ; Ibrahim, SH; Werneburg, NW | 1 |
1 other study(ies) available for enzastaurin and Non-alcoholic Fatty Liver Disease
Article | Year |
---|---|
Glycogen synthase kinase-3 (GSK-3) inhibition attenuates hepatocyte lipoapoptosis.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Base Sequence; Cell Line; Cells, Cultured; DNA Primers; Enzyme Activation; Enzyme Inhibitors; Fatty Liver; Gene Knockdown Techniques; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Hepatocytes; Humans; Indoles; JNK Mitogen-Activated Protein Kinases; Mice; Non-alcoholic Fatty Liver Disease; Palmitates; Proto-Oncogene Proteins; RNA, Small Interfering; Signal Transduction; Tumor Suppressor Proteins | 2011 |